883-09-0

Basic information

• Product Name: 5,7-dihydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one
• Synonyms: 5,7-dihydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one;4H-1-BENZOPYRAN-4-ONE,2,3-DIHYDRO-5,7-DIHYDROXY-2,2-DIMETHYL-;OTAVA-BB 1090423
• CAS NO: 883-09-0
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21
• Mol File: 883-09-0.mol

Chemical Properties

• Boiling Point: 404.3°C at 760 mmHg
• Flash Point: 162.7°C
• Appearance: /
• Density: 1.308g/cm³
• Vapor Pressure: 4.08E-07mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 5,7-dihydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-dihydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one(883-09-0)
• EPA Substance Registry System: 5,7-dihydroxy-2,2-dimethyl-2,3-dihydro-4H-chromen-4-one(883-09-0)

Safety Data

• Hazardous Substances Data: 883-09-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthesis, p. 545, 1985 DOI: 10.1055/s-1985-31270

InChI:InChI=1/C11H12O4/c1-11(2)5-8(14)10-7(13)3-6(12)4-9(10)15-11/h3-4,12-13H,5H2,1-2H3

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 108-73-6 3,5-dihydroxyphenol 
• 37637-88-0 N-formamido-3-methyl-2-butenamide 

Downstream Products

• 50386-14-6 7-benzyloxy-2,2-dimethyl-5-hydroxy-4-chromanone 
• 21421-64-7 5,7-dihydroxy-2,2-dimethyl-chroman-4-one-(2,4-dinitro-phenylhydrazone) 
• 63789-85-5 2,3-dihydro-2,2-dimethyl-5-hydroxy-7-(1-methyl-4-phenylbutoxy)-4H-1-benzopyran-4-one 
• 888027-28-9 [(4,8,8-trimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-5-yl)oxy]acetic acid 
• 69025-98-5 (+/-)-6,6aβ,7,8,10,10aα-hexahydro-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)-9H-dibenzopyran-9-one 
• 63789-90-2 2,3-dihydro-5-hydroxy-3-(hydroxymethylene)-2,2-dimethyl-7-(1-methyl-4-phenylbutoxy)-4H-1-benzopyran-4-one 
• 69025-89-4 (6aR,10aR)-1-Amino-6,6-dimethyl-3-(1-methyl-4-phenyl-butoxy)-6,6a,7,8,10,10a-hexahydro-benzo[c]chromen-9-one 
• 69025-90-7 (+/-)-1-amino-6aβ,7,8,9,10,10aα-hexahydro-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)-6H-dibenzopyran-9β-ol 
• 63789-94-6 (+/-)-6,6a,7,8-tetrahydro-1-hydroxy-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)-9H-dibenzopyran-9-one 
• 129657-94-9 2,3-dihydro-2,2-dimethyl-5-hydroxy-3-(3-oxobutyl)-7-(1-methyl-4-phenylbutoxy)-4H-1-benzopyran-4-one 
• 69025-92-9 (+/-)-6,6aβ,7,8,10,10aα-hexahydro-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)spiro<9H-dibenzopyran-9,2'-<1,3>dioxolane> 
• 63790-11-4 (+/-)-6,6aβ,7,8,10,10aα-hexahydro-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)spiro<9H-dibenzopyran-9,2'-<1,3>dioxolan>-1-ol 
• 69025-94-1 (+/-)-6,6aβ,7,8,10,10aα-hexahydro-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)spiro<9H-dibenzopyran-9,2'-<1,3>dioxolan>-1-amine 
• 129657-91-6 (+/-)-<6aβ,7,8,9,10,10aα-hexahydro-1,9β-dihydroxy-6,6-dimethyl-3-(1-methyl-4-phenylbutoxy)-6H-dibenzopyran-4-yl>phosphonic acid diethyl ester 

Relevant articles and documents

Drug efficacy of novel 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans; evaluated via DNA gyrase inhibition, bacterial cell wall lesion and antibacterial prospective

In this study, novel 3-O-methoxy-4-halo, disubstituted-5,7-dimethoxy chromans with bacterial cell wall degrading potentials were synthesized, characterized and evaluated as DNA gyrase inhibitors and antibacterial agents. Compounds were showed a broad spectrum of antimicrobial activity against both Gram+ve bacteria (S. aureus (MTCC 3160), C. diphtheriae (MTCC 116), S. pyogenes (MTCC 442)) and Gram?ve bacteria (E. coli (MTCC 443), P. aeruginosa (MTCC 424), K. pneumoniae (MTCC 530)). Further, a molecular docking study was carried out to get more insight into the binding mode of present study compounds to target proteins (PDB ID: 2XCT (S. aureus DNA gyrase A), PDB ID: 3G75 (S. aureus DNA gyrase B), PDB ID: 3L7L (Teichoic acid polymerase). In the results, 14 > 20 > 24 > 12 > 18 > 17 were found as the most active against almost all executed activities in this study. The predicted Lipinski's filter scores, SAR, pharmacokinetic/pharmacodynamics, and ADMET properties of these compounds envisioned the druggability prospects and the necessity of further animal model evaluations of 3-O-methoxy-4-halo disubstituted 5,7-dimethoxy chromans to establish them as an effective and future antibiotics.

Chromanol derivatives - A novel class of CETP inhibitors

Based on our former development candidate BAY 38-1315, optimization efforts led to the discovery of a novel chemical class of orally active cholesteryl ester transfer protein (CETP) inhibitors. The chromanol derivative 19b is a highly potent CETP inhibitor with favorable pharmacokinetic properties suitable for clinical studies. Chemical process optimization furnished a robust synthesis for a kilogram-scale process.

USE OF CHROMAN-4-ONE DERIVATIVES

The invention relates to the use of compounds of the formula (I) or of a composition comprising at least one compound of the formula (I), containing radicals as described in the claims, for the care, preservation or improvement of the general state of the skin or hair.

Total synthesis of (±)-glyflavanone by a rigid quaternary ammonium salt

Total synthesis of (±)-glyflavanones and glychalcones was accomplished starting from the known 1-(5-hydroxy-7-methoxy-2,2-dimethyl-2H- chromen-6-yl)ethanone (6). A new approach to synthesis of flavanones, based on a high yielding N-benzylcinchoninium salt

Indole derivative having piperidine ring

The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

Modified coumarins. 13. Synthesis of cyclopentane-annelated pyranocoumarins

Modified pyranocoumarins containing a condensed cyclopentane fragment were synthesized by adjoining a 2,2-dimethyltetrahydropyran ring to a 2,3-dihydrocyclopenta[c]chromen-4-one system and annelation of a pyrone ring to a 2,2-dimethylchromane.

Synthesis of azacridone A

The first total synthesis of the only known naturally occurring azaacridone alkaloid (1) has been achieved in 10 steps from phloroglucinol. A variety of ortholithiation reactions are described, and a method for overcoming the originally unfavorable regiochemistry of one of them is provided.

Total synthesis of seco-lateriflorone

A convergent strategy toward the synthesis of lateriflorone (5) is described. Our approach is based on biosynthetic considerations and draws on a sequence of prenylation, oxygenation and Claisen reactions for the construction of chromenequinone 6, and a tandem Claisen/Diels-Alder reaction cascade for the synthesis of caged tricycle 7. Union of fragments 6 and 7 led to the synthesis of seco-lateriflorone (49).

Atom economy. Palladium-catalyzed formation of coumarins by addition of phenols and alkynoates via a net C-H insertion

A strategy to achieve ortho substitution of phenols initiated by an ortho-palladation to create coumarins was examined. Indeed, treatment of alkynoates with electron-rich phenols in the presence of a palladium catalyst and an acid does generate coumarins. The scope of the reaction with respect to the phenol and the alkynoates is defined. With unsymmetrical aromatic substrates, generally good regioselectivity that reflects the HOMO coefficients can be observed. In the course of these studies, numerous important naturally occurring coumarins have been synthesized, including fraxinol methyl ether, ayapin, herniarin, xanthoxyletin, and alloxanthoxyletin. The fact that a Pd(0) is the precatalyst rather than a Pd(+2) species and that an acid that reduces Pd(+2) salts, formic acid, functions better than other carboxylic acids raises doubts about the initial working hypothesis. A novel mechanism involving a palladium phenoxide formed from a hydridopalladium carboxylate and phenol is invoked to rationalize the results.

Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3′R,4′R)-3′,4′-di-O-(S)-camphanoyl-(+)-cis- khellactone analogues

A series of disubstituted 3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogues (1-10) were synthesized and evaluated for inhibition of HIV-1 replication in H9 lymphocytes. 5-Methoxy-4-methyl DCK (8) was the most promising compound with an EC50 value of 7.21 × 10-6 μM and a therapeutic index of >2.08 × 10,7 which were much better than those of lead compound DCK in the same assay. Another six disubstituted DCK analogues (1-5 and 7) were more potent than AZT but less active than DCK. Conformational analysis suggested that resonance of the coumarin system is an essential structural feature for potent anti-HIV activity. Steric compression of C(4) and C(5) substituents of the coumarin moiety can reduce the overall planarity and thus resonance of the coumarin nucleus, resulting in a decrease or lack of anti-HIV activity.